On April 23, 2020 EpimAb Biotherapeutics, an emerging Shanghai-based biopharmaceutical company specializing in bispecific antibodies, and the QIMR Berghofer Medical Research Institute (QIMR Berghofer), a non-profit research organization based in Brisbane, Australia, reported a research collaboration and license agreement to evaluate novel target combinations for their application using EpimAb’s bispecific antibody format, Fabs-In-Tandem Immunoglobulin (FIT-Ig) (Press release, EpimAb Biotherapeutics, APR 23, 2020, View Source [SID1234556509]). Under the terms of the agreement, EpimAb will be granted an exclusive license to QIMR Berghofer’s novel target combinations identified by Professors Bill Dougall and Mark Smyth to develop novel bispecific antibodies. During the collaboration, EpimAb’s novel bispecific antibodies will be tested in QIMR Berghofer’s pre-clinical models. Financial details were not disclosed.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"QIMR Berghofer is one of the pioneering institutes in the discovery of immuno-oncology mechanisms which are playing an important role in today’s treatment of cancer. We are proud to collaborate with QIMR Berghofer to identify novel target combinations as EpimAb enters the next stage of growth," said Dr. Chengbin Wu, CEO and founder of EpimAb. "With our lead program in clinical trials and several to follow, we have shown the ability of our FIT-Ig technology to rapidly generate innovative bispecific antibodies. We look forward to using the technology to evaluate novel bispecific target pairs developed under our collaboration and select viable pairs to broaden our pipeline."
"The bispecifics field has opened up new potential avenues to treat cancer and EpimAb’s bispecific antibody format has unique capabilities and features. EpimAb’s proprietary platform technology and experienced team will allow us to further evaluate some of our most recent discoveries, hopefully bringing novel immunotherapies to future cancer patients," said Professor Mark Smyth, Senior Scientist and Immunology Department Coordinator at QIMR Berghofer.